Accuray, which is developing an intelligent robotic radiosurgery system for the treatment of solid tumors in the human body, filed the terms for its IPO on Tuesday. The company plans to offer 13.3 million shares at a range of $14-$16. JP Morgan and UBS are managing the deal which has a proposed market cap of $885 million. Timing has yet to be announced.
